CytoDyn Logo
Eleven HIV Patients Successfully Reach One Year of Full Virologic Suppression in PRO 140 Monotherapy Phase 2b Extension Study
December 01, 2015 08:30 ET | CytoDyn
VANCOUVER, Wash., Dec. 1, 2015 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV)...
CytoDyn Logo
CytoDyn Hires New Senior Vice President of Manufacturing for PRO 140
November 24, 2015 06:30 ET | CytoDyn
VANCOUVER, Wash., Nov. 24, 2015 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV)...
CytoDyn Logo
CytoDyn Announces Investment Community Conference Call
November 18, 2015 06:30 ET | CytoDyn
VANCOUVER, Wash., Nov. 18, 2015 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with human immunodeficiency...
CytoDyn Logo
CytoDyn Injects First Patient in Its Current Phase 3 Study
October 22, 2015 06:30 ET | CytoDyn
VANCOUVER, Wash., Oct. 22, 2015 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV)...
CytoDyn Logo
CytoDyn Files an IND and Full Protocol for Phase 2 Study in GvHD
October 20, 2015 06:30 ET | CytoDyn
VANCOUVER, Wash., Oct. 20, 2015 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV)...
CytoDyn Logo
HIV Patients Successfully Reach One Year of Virologic Suppression in PRO 140 Monotherapy Study
September 21, 2015 06:30 ET | CytoDyn
VANCOUVER, Wash., Sept. 21, 2015 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV)...
CytoDyn Logo
Cytodyn Initiates First Clinical Site for Phase 3 Trial of PRO 140
August 05, 2015 16:01 ET | CytoDyn
VANCOUVER, Wash., Aug. 5, 2015 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV)...
CytoDyn Logo
CytoDyn Completes Qualification of PRO 140 Material for Phase 3
July 29, 2015 06:30 ET | CytoDyn
VANCOUVER, Wash., July 29, 2015 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV)...
CytoDyn Logo
Evidence of HIV Suppression With PRO 140 Monotherapy Reaching Nearly 11 Months
July 15, 2015 06:30 ET | CytoDyn
CytoDyn to Request Meeting With FDA to Discuss Registration Pathway for PRO 140 Monotherapy Indication Dr. Paul J. Maddon, an Inventor of PRO 140, Named Senior Science Advisor VANCOUVER, Wash.,...
CytoDyn Logo
CytoDyn to Expand Clinical Applications for PRO 140 Beyond Therapy for HIV
June 24, 2015 06:30 ET | CytoDyn
VANCOUVER, Wash., June 24, 2015 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus...